Search
ibrexafungerp (Brexafemme)
Indications:
- treatment of vaginal yeast infections (FDA-approved) [2]
Contraindications:
- pregnancy
Dosage:
- one day oral therapy
Tabs: 150 mg
Adverse effects:
- diarrhea
- nausea/vomiting
- abdominal pain
- dizziness
Drug interactions:
- CYP3A inhibitor
Antimicrobial activity:
- Candida glabrata
General
antifungal agent
References
- Gamal A, Chu S, McCormick TS et al
Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development:
Overview of Antifungal Activity Against Candida glabrata.
Front. Cell. Infect. Microbiol., 11 March 2021
PMID: 33791244 PMCID: PMC8006402 Free PMC article
https://www.frontiersin.org/articles/10.3389/fcimb.2021.642358/full
- Frellick M
FDA Approves Ibrexafungerp for Vaginal Yeast Infection.
Medscape - Jun 02, 2021.
https://www.medscape.com/viewarticle/952312